Ceryvyn Therapeutics Limited CYVNY
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -97.67% | -98.43% | -98.65% | -87.59% | -79.44% |
| Total Other Revenue | -- | -103.30% | -106.41% | -57.15% | -8.61% |
| Total Revenue | -99.60% | -101.73% | -103.20% | -70.63% | -42.37% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -99.60% | -101.73% | -103.20% | -70.63% | -42.37% |
| SG&A Expenses | -78.93% | -53.91% | -23.44% | 22.23% | 97.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -90.11% | -20.88% | 143.17% | 143.17% | 143.17% |
| Total Operating Expenses | -94.87% | -75.53% | -59.61% | -39.08% | -18.30% |
| Operating Income | 94.86% | 75.51% | 59.56% | 39.04% | 18.26% |
| Income Before Tax | 225.79% | 193.66% | 172.58% | 104.06% | 25.25% |
| Income Tax Expenses | 97.88% | 93.99% | 91.45% | 60.67% | 25.11% |
| Earnings from Continuing Operations | 231.27% | 197.86% | 175.97% | 105.89% | 25.25% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 231.27% | 197.86% | 175.97% | 105.89% | 25.25% |
| EBIT | 94.86% | 75.51% | 59.56% | 39.04% | 18.26% |
| EBITDA | 94.87% | 75.51% | 59.56% | 39.04% | 18.26% |
| EPS Basic | 220.31% | 172.81% | 150.09% | 101.24% | 60.90% |
| Normalized Basic EPS | 215.60% | 169.89% | 147.98% | 100.24% | 60.94% |
| EPS Diluted | 220.31% | 172.81% | 150.09% | 101.24% | 60.90% |
| Normalized Diluted EPS | 215.60% | 169.89% | 147.98% | 100.24% | 60.94% |
| Average Basic Shares Outstanding | 10.23% | 20.89% | 34.62% | 57.61% | 91.90% |
| Average Diluted Shares Outstanding | 10.23% | 20.89% | 34.62% | 57.61% | 91.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |